- Rekrutierung läuftNiraparib vs. Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicenter randomised phase III trial)
- Rekrutierung läuft
A First – in Human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3
Molekulare Marker - Rekrutierung läuft
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
EUDRA-CT Nummer geändert 18.12.2023
von 2021-001188-26 auf 2023-503651-10-00
Indikationen- Brustkrebs (Mammakarzinom)
- Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)
- Gebärmutterhalskrebs (Zervixkarzinom)
- Eierstockkrebs (Ovarialkarzinom)
- Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)
- Nierenzellkarzinom
- Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)
- Magenkarzinom
- Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)
- Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)
- Bauchspeicheldrüsenkrebs (Pankreaskarzinom)
- Lungentumoren
- Nicht-kleinzelliges Bronchialkarzinom (NSCLC)
- Kopf/Hals Tumoren
- Kopf-Hals-Malignome
- Hirntumore (ZNS Tumore)
- Akustikusneurinom (Vestibularis-Schwannom)
- Hauttumoren
- Malignes Melanom
- Rekrutierung läuftA Phase 3, Randomized, Open-Label, Multicenter Study to 'Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Subjects with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
- Rekrutierung läuft
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)
- Rekrutierung läuftCAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular patterns of Ribociclib efficacy and resistance in advanced breast cancer patientsIndikationen
- Rekrutierung läuftFUTURE platform trialA phase II platform trial of futibatinib in combinaton with (chemo)immunotherapy in colorectal cancer and other solid tumor entities
- Rekrutierung läuftPreventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III "PREVENT" Trial of the AIO /CAOGI /ACO
- Rekrutierung läuftA Phase III, Randomized, open-label study evaluating the efficacy and safety of Divarasib and Pembrolizumab versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in patients with previously untreated, KRAS G12C-mutated, advanced or metastatic non-squamous non−small cell lung cancer
- Rekrutierung läuft
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]
Molekulare Marker